ONO-2808

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Parkinson

#DrugCompanyPhaseTrials

1

Pletal

Otsuka

Phase 2

12

Standard Treatment

Boehringer Ingelheim

Phase 2

13

ONO-2808

Ono Pharmaceutical Co. Ltd

Phase 3

14

A-Dopamine

UUniversity Hospital, Lille

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics1 trial

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

Completed·Ono Pharmaceutical Co. Ltd·Phase 1·NCT04578028·94 enrolled

Parkinson1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)

Not yet recruiting·Ono Pharmaceutical Co. Ltd·Phase 3·NCT07825402·486 enrolled

Multiple System Atrophy, MSA1 trial

A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting·Ono Pharmaceutical Co. Ltd·Phase 2·NCT05923866·92 enrolled

Details

Drug Info

Related News